Sharp Downside In Esperion Shares May Be An Overreaction

Loading...
Loading...

As shares of Esperion Therapeutics Inc ESPR plunged more than 40 percent over Wednesday's trading session, numerous analysts were out adjusting recommendations, price targets and estimates.

Citi analyst Joel Beatty made some concerning comments despite a maintained Buy rating. The analyst cut his price target on Esperion shares from $36 to $22.

Amid news the FDA has not yet agreed to LDL "as an approvable surrogate endpoint for [Esperion's] cholesterol agent bempedoic acid," according to Beatty, he voiced concern the company may not receive U.S. approval until 2023, and not until 2020 in Europe.

On the more bullish side of things, Beatty said, "We see the post-close stock price decrease of ~30% as an overreaction given that investors were already mixed on whether the uncertainty around endpoints would be resolved by this update."

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsMovers
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...